Baidu
map

癌症化疗药物新突破:科学家发现锇类化合物的抗癌作用

2017-02-14 佚名 Medicalxpress

华威大学研究人员第一次见证了由他们发现的有机金属化合物可以以癌细胞为靶点,从癌细胞内部将其摧毁。



华威大学研究人员第一次见证了由他们发现的有机金属化合物可以以癌细胞为靶点,从癌细胞内部将其摧毁。

Peter J. Sadler教授和他的化学团队已证明,有机锇FY2626化合物能对癌细胞的薄弱环节进行定位并进行攻击,从而杀死癌细胞。

这是自现有的抗癌药物顺铂以来,发现的第一个用于抗癌的锇基化合物,其抗癌活性是顺铂的50倍。

利用欧洲同步辐射装置(ESRF),研究人员分析了有机锇FY26对卵巢癌细胞的作用:检测X射线荧光光排放追踪细胞内化合物的活性。

观察纳米焦点下的肿瘤细胞,可以看到一个前所未有的微小细节水平——能检测到线粒体。

在癌细胞中,线粒体DNA中存在错误和突变,使它们变得很弱,容易受到攻击。

FY26已经将自己定位于线粒体的薄弱点——从内部攻击和破坏癌细胞。

研究人员也能看到由人体产生的天然金属,如锌和钙在细胞周围移动。众所周知,钙对细胞的功能有着重要影响,并认为钙有助于FY26作用到肿瘤的最佳位置并对肿瘤进行攻击。

目前超过一半的癌症化疗药物为铂化合物,且用于治疗已有40余年,所以有必要探索其他贵金属对癌症的治疗价值。

尽管这项研究是针对卵巢癌细胞进行的,但其结果适用于其他类型的癌症。

相比于顺铂,FY26已经显示对正常细胞和癌细胞有更高的选择性。

Sadler教授表示,这项研究可能会促使新的癌症治疗药物应用于临床,我们迫切需要有抗药性和副作用少的新的抗癌药物出现。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2058691, encodeId=305420586918a, content=<a href='/topic/show?id=acdce132383' target=_blank style='color:#2F92EE;'>#癌症化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71323, encryptionId=acdce132383, topicName=癌症化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jan 11 21:08:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724917, encodeId=b8811e2491725, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Thu May 04 20:08:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802386, encodeId=b280180238684, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Aug 17 00:08:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906333, encodeId=6fca1906333c9, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Wed Aug 30 22:08:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177107, encodeId=92cf1e710711, content=厉害,又有新的技术方法了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Mon Feb 20 09:44:01 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506705, encodeId=c68a1506e054b, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581744, encodeId=945c1581e443d, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2058691, encodeId=305420586918a, content=<a href='/topic/show?id=acdce132383' target=_blank style='color:#2F92EE;'>#癌症化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71323, encryptionId=acdce132383, topicName=癌症化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jan 11 21:08:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724917, encodeId=b8811e2491725, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Thu May 04 20:08:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802386, encodeId=b280180238684, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Aug 17 00:08:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906333, encodeId=6fca1906333c9, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Wed Aug 30 22:08:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177107, encodeId=92cf1e710711, content=厉害,又有新的技术方法了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Mon Feb 20 09:44:01 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506705, encodeId=c68a1506e054b, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581744, encodeId=945c1581e443d, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
    2017-05-04 zxxiang
  3. [GetPortalCommentsPageByObjectIdResponse(id=2058691, encodeId=305420586918a, content=<a href='/topic/show?id=acdce132383' target=_blank style='color:#2F92EE;'>#癌症化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71323, encryptionId=acdce132383, topicName=癌症化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jan 11 21:08:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724917, encodeId=b8811e2491725, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Thu May 04 20:08:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802386, encodeId=b280180238684, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Aug 17 00:08:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906333, encodeId=6fca1906333c9, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Wed Aug 30 22:08:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177107, encodeId=92cf1e710711, content=厉害,又有新的技术方法了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Mon Feb 20 09:44:01 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506705, encodeId=c68a1506e054b, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581744, encodeId=945c1581e443d, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2058691, encodeId=305420586918a, content=<a href='/topic/show?id=acdce132383' target=_blank style='color:#2F92EE;'>#癌症化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71323, encryptionId=acdce132383, topicName=癌症化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jan 11 21:08:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724917, encodeId=b8811e2491725, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Thu May 04 20:08:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802386, encodeId=b280180238684, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Aug 17 00:08:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906333, encodeId=6fca1906333c9, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Wed Aug 30 22:08:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177107, encodeId=92cf1e710711, content=厉害,又有新的技术方法了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Mon Feb 20 09:44:01 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506705, encodeId=c68a1506e054b, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581744, encodeId=945c1581e443d, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2058691, encodeId=305420586918a, content=<a href='/topic/show?id=acdce132383' target=_blank style='color:#2F92EE;'>#癌症化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71323, encryptionId=acdce132383, topicName=癌症化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jan 11 21:08:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724917, encodeId=b8811e2491725, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Thu May 04 20:08:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802386, encodeId=b280180238684, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Aug 17 00:08:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906333, encodeId=6fca1906333c9, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Wed Aug 30 22:08:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177107, encodeId=92cf1e710711, content=厉害,又有新的技术方法了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Mon Feb 20 09:44:01 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506705, encodeId=c68a1506e054b, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581744, encodeId=945c1581e443d, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
    2017-02-20 wmu姿

    厉害,又有新的技术方法了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2058691, encodeId=305420586918a, content=<a href='/topic/show?id=acdce132383' target=_blank style='color:#2F92EE;'>#癌症化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71323, encryptionId=acdce132383, topicName=癌症化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jan 11 21:08:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724917, encodeId=b8811e2491725, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Thu May 04 20:08:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802386, encodeId=b280180238684, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Aug 17 00:08:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906333, encodeId=6fca1906333c9, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Wed Aug 30 22:08:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177107, encodeId=92cf1e710711, content=厉害,又有新的技术方法了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Mon Feb 20 09:44:01 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506705, encodeId=c68a1506e054b, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581744, encodeId=945c1581e443d, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2058691, encodeId=305420586918a, content=<a href='/topic/show?id=acdce132383' target=_blank style='color:#2F92EE;'>#癌症化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71323, encryptionId=acdce132383, topicName=癌症化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jan 11 21:08:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724917, encodeId=b8811e2491725, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Thu May 04 20:08:00 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802386, encodeId=b280180238684, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu Aug 17 00:08:00 CST 2017, time=2017-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906333, encodeId=6fca1906333c9, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Wed Aug 30 22:08:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=177107, encodeId=92cf1e710711, content=厉害,又有新的技术方法了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=071c2012037, createdName=wmu姿, createdTime=Mon Feb 20 09:44:01 CST 2017, time=2017-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506705, encodeId=c68a1506e054b, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581744, encodeId=945c1581e443d, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Thu Feb 16 02:08:00 CST 2017, time=2017-02-16, status=1, ipAttribution=)]

相关资讯

Science子刊:细菌杀死癌症?

利用细菌对抗癌症?近日,来自于韩国的科学家们证实了可行性。他们选择了一种无害的沙门氏菌,对其进行基因工程改造后确保细菌能够分泌一种关键蛋白。借助这一蛋白,细菌能够有效抑制癌症扩散,同时它们还会激活免疫系统,促使它们攻击癌细胞。

JNM:科学家或有望开发出抵御多种癌症的新型疗法

近日,一项刊登在国际杂志The Journal of Nuclear Medicine上的研究报告中,来自澳大利亚的研究人员通过研究阐明了靶向作用生长抑素受体的肽类受体放射性核素疗法在治疗除神经内分泌瘤(NETs)之外的其它恶性肿瘤上的潜能;研究者表示,将FDA批准的诊断显像剂Netspot与

神奇的报告!2050年可能没有人会因为癌症死亡

当前人们普遍认为,癌症患者的数量在不断增加。但最新一项研究表明,得益于更好的技术、药物和生活方式,到本世纪中叶,几乎没有人再因为癌症而死亡。

Nature:重磅!癌症微环境自噬促进肿瘤生长

在一项新的研究中,来自挪威、匈牙利和美国的研究人员发现癌细胞通过窃取周围细胞的能量进行生长。

假如有更多的基因检测,就不会遗漏7%的风险人群

最新调查发现,结直肠癌遗传性易感基因突变的发生率为10%,比传统的认识高了7%。调查人员呼吁,假如有更多的基因检测,就不会遗漏7%的风险人群,还可以改善治疗后的护理。前几日,JAMA上的调查也发现,癌症患者对基因检测是想要却不可得。无论是JAMA还是JCO上的调查,都反映了基因检测在癌症患者中的普及不够到位。

盘点:如何通过构建模型来助力人类疾病研究?

构建模型一直以来都是科学家们用以进行科学研究的关键方法,比如科学家们经常会构建疾病模型、动物模型、利用计算机开发出数学算法模型来用于人类疾病、药物开发等领域的研究,那么近年科学家利用模型进行研究取得了哪些突破性进展呢?本文中小编对此进行了整理,分享给各位! 【1】mBio  eLife:利用小型3D球体模型就能够有效抵御结核病 doi:10.7554/eLife.21283&

Baidu
map
Baidu
map
Baidu
map